CVRX

Cvrx, Inc.

• TipRanks·3d ago

  CVRx’s BAROSTIM Registry: Real‑World Hypertension Data That Could Move the Stock

• TipRanks·3d ago

  CVRX’s Barostim Heart Failure Registry: Real‑World Data That Matters for Investors

• TipRanks·3d ago

  BAROSTIM NEO Trial Update: Long-Term Hypertension Data in Focus for CVRX Investors

• PR Newswire·08/26 17:08

  HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

• TipRanks·08/24 12:35

  Jorey Chernett urges CVRx board to commence formal sales process

• Dow Jones·08/24 12:30

  Press Release: Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer

• TipRanks·08/19 00:12

  CVRx Earnings Call Balances Growth With New Risks

• Dow Jones·08/17 11:19

  CVRx Price Target Cut to $5.00/Share From $13.00 by Cantor Fitzgerald

• Dow Jones·08/17 11:19

  CVRx Is Maintained at Overweight by Cantor Fitzgerald

• TipRanks·08/12 11:25

  Analyst Reaffirms Buy on CVRx, Maintains Unchanged $5 Price Target Amid Improving Reimbursement and Growth Outlook

• TipRanks·08/11 13:40

  Analysts Conflicted on These Healthcare Names: CVRx (CVRX), Jazz Pharmaceuticals (JAZZ) and Disc Medicine (IRON)

• Dow Jones·08/11 11:06

  *CVRx Says Verrastro Has More Than 30 Years of Medical Device Sales, Marketing Experience >CVRX

• Dow Jones·08/11 11:01

  *CVRx: Paul Verrastro to Assume Role of Interim Head of Sales, Effective Immediately >CVRX

• Dow Jones·08/11 11:01

  *CVRx: Robert John, Chief Rev Officer, Will Depart Co >CVRX

• Dow Jones·08/11 11:00

  Press Release: CVRx Announces Sales Leadership Transition